The prospective SOARA study will measure how often a 98%-specific ovarian cancer screening blood test leads to invasive procedures.
Dawn Mattoon, PhD
Advertisement
Mattoon is the CEO of Mercy BioAnalytics.
Articles by Dawn Mattoon, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
Wen Shen, MD, on steering patients to evidence-based menopause care
2
FAQ: What you need to know about ACOG's new maternal immunization schedule
3
Garima Sharma, MD, on cardio-obstetrics framework, cardiovascular risk
4
The annual well-woman visit needs an upgrade
5